-
2024 Lung Cancer Precision Therapy Academic Conference | Professor Jianhua Chang Highlights Key Takeaways from the 2024 Lung Cancer Precision Therapy
Oncology Frontier ：The Lung Cancer Precision Therapy Academic Conference has become a recognized academic brand. Could you tell us about its origins, development, and goals? What impact do you hope…
-
SABCS 2024 | Dr. Qingyuan Zhang: A New Breakthrough with SIM0270 in ER+/HER2- Advanced Breast Cancer
At the recent San Antonio Breast Cancer Symposium (SABCS), Professor Jiong Wu from Fudan University Shanghai Cancer Center presented the latest findings from a Phase I study on SIM0270 (Abstract Number: PS14-03). SIM0270, an innovative brain-penetrant oral selective estrogen receptor degrader (SERD), demonstrated significant clinical efficacy and excellent tolerability in patients with ER+/HER2- advanced breast…
-
Dr. Benlong Yang: Advances in Precision Treatment for HER2-Positive Breast Cancer | 2024 Straits Breast Cancer Forum
With the rapid advancement of medical technology, the concept of precision medicine has been widely applied in the diagnosis and treatment of breast cancer. At the 47th San Antonio Breast Cancer Symposium (SABCS) in 2024, Chinese research gained significant attention, showcasing groundbreaking achievements in breast cancer treatment. During the “2024 Straits Breast Forum and the…
-
Deep Learning-Based Prognostication for Hepatocellular Carcinoma: A Multimodal Imaging Approach
Study Design This multicenter study involved 1,231 patients with histology-confirmed HCC who underwent liver resection. The internal cohort, comprising patients from four centers in Chinese Hong Kong, was divided into…
-
JAMA Network Open丨Dr. Fanpu Ji’s Team: Trends and Projections of Hepatocellular Carcinoma Mortality Rates in the U.S.
Background and Key Findings Globally, the burden of liver cancer is significant. In 2020, it was the sixth most common cancer and the third leading cause of cancer deaths worldwide.…
-
From Risk-Based to Disease-Oriented Treatment: Response, Remission, and Cure in the MRD Era of Colorectal Cancer
Traditionally, decisions regarding adjuvant chemotherapy after colorectal cancer surgery have been based on a patient’s risk of recurrence, determined by TNM staging and histopathological features. However, emerging evidence suggests that these guidelines, in place since 2004, may not be the most effective approach and could be inadequate. In fact, surgery alone has already achieved high…
-
Dr. Petrv Tsarkov:Clinical Controversies and Considerations in Lymphadenectomy for Colorectal Cancer
Lateral lymph node (LLN) metastasis in locally advanced rectal cancer is associated with patient prognosis. However, the clinical significance of lateral lymph node dissection (LLND) has always been a matter of debate in the academic community. We have invited Dr. Petrv Tsarkov from Chechenov State Medical University in Moscow to share his insights and thoughts…
-
Dr. Ashwin Somasundaram：How Should Adjuvant Therapy Be Decided for High-Risk MSI-H Stage II Colorectal Cancer?
The decision on whether high-risk MSI-H (microsatellite instability-high) stage II colorectal cancer patients should receive adjuvant therapy remains controversial. Dr. Ashwin Somasundaram, a medical professor at the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, shares his insights on this complex issue.
Connecting Medical Expertise through Media